Report

Teaser, summary, work performed and final results

Periodic Reporting for period 1 - ZENEO (ZENEO® Adrenaline Needle-free adrenaline pre-filled autoinjector rescues you from an anaphylactic shock)

Teaser

Anaphylactic shock is a rare, severe and rapid onset allergic reaction that can be treated with the injection of Adrenaline, but if left untreated may cause death by asphyxia in 20 minutes. Adrenaline auto-injectors are needle-based pre-filled devices for self-injection into...

Summary

Anaphylactic shock is a rare, severe and rapid onset allergic reaction that can be treated with the injection of Adrenaline, but if left untreated may cause death by asphyxia in 20 minutes. Adrenaline auto-injectors are needle-based pre-filled devices for self-injection into the muscle of the outer side of the thigh. User tests of some leading auto-injectors show a poor success rate after six weeks (42% or 43% depending on the auto-injectors), half of errors being that people do not wait long enough (above 3 seconds) while the needle injects inside the muscle.

Work performed

During the Feasibility Study period, Crossject finetuned the market approach and essential arguments, focusing on the market drivers and advantages versus current solutions and the cost to take ZENEO® Adrenaline to TRL9. A sales forecast for three years post-project was prepared based on market analysis.

Final results

Crossject has used a combination of cutting-edge technologies to develop ZENEO® in such a way that it is capable of injecting a tiny jet of Adrenaline through a patient’s skin by propelling it at very high pressure and speed. All in all ZENEO® has been developed to relieve fear of needles; eliminate all risks of injury; and perform a true intramuscular injection by non-healthcare professionals due to its quick, one-handed use, thus excluding any risk of contamination and pollution of needles disposal. Crossject aims to be a leader of emergency use drug –device pharmaceutical products to save lives simply.

Website & more info

More info: https://www.crossject.com/en.